WY-14643 (Pirinixic Acid): Unraveling PPARα Signaling and Liver Regeneration

Introduction: WY-14643 at the Frontier of Metabolic and Regenerative Research

WY-14643, also known as Pirinixic Acid, stands as a cornerstone tool in the exploration of peroxisome proliferator-activated receptor alpha (PPARα) biology. As a highly potent and selective PPARα agonist, it has enabled breakthroughs in metabolic disorder research, lipid metabolism regulation, and anti-inflammatory signaling. Yet, recent discoveries—particularly regarding the YAP-TEAD axis and liver regeneration—have propelled WY-14643 into new scientific territory. In this article, we provide a comprehensive, mechanistic, and application-focused perspective on WY-14643 (Pirinixic Acid), with special emphasis on its role in bridging metabolic regulation, inflammation, and tissue regeneration.

Mechanism of Action of WY-14643 (Pirinixic Acid): Precision in PPARα Modulation

PPARα Activation and Downstream Effects

WY-14643 is a synthetic ligand that selectively activates PPARα, a nuclear receptor governing the transcription of genes involved in fatty acid β-oxidation, lipid transport, and inflammatory regulation. With an IC50 value of 10.11 µM for human PPARα, WY-14643 exhibits high potency and selectivity, making it an indispensable tool for dissecting the PPAR signaling pathway in both basic and translational research.

Upon binding to PPARα, WY-14643 induces conformational changes that promote heterodimerization with retinoid X receptor (RXR), recruitment of co-activators, and enhanced transcription of target genes. This molecular cascade leads to:

• Lipid metabolism regulation: Increased expression of enzymes mediating fatty acid uptake, oxidation, and clearance of triglyceride-rich lipoproteins.
• Anti-inflammatory activity: Suppression of pro-inflammatory genes, notably VCAM-1 and cytokines involved in TNF-α mediated inflammation.
• Metabolic homeostasis: Reduction in plasma glucose, triglycerides, and improvement in insulin sensitivity in preclinical models.

Beyond PPARα: Dual Agonism and Cellular Impact

Structural modifications, such as aliphatic α-substitution of WY-14643, have been shown to enhance its agonistic activity on both PPARα and PPARγ, generating balanced dual PPARα/γ agonists within the lower micromolar range. This duality opens avenues for research into combinatorial metabolic and anti-inflammatory interventions, extending the compound’s utility beyond conventional single-receptor targeting.

Deciphering the YAP-TEAD-PPARα Axis: Insights from Liver Regeneration Models

The YAP-TEAD Pathway Intersects with PPARα Signaling

While previous articles have highlighted the pivotal role of WY-14643 in metabolic disorder modeling and inflammation (see this comparative review), our focus here is on an emerging mechanistic intersection: the YAP-TEAD pathway’s mediation of PPARα-induced hepatomegaly and liver regeneration.

In a landmark study (Wang et al., HEP-21-0169), researchers demonstrated that administration of WY-14643 at 100 mg/kg/day in murine models triggered marked hepatomegaly and robust liver regeneration. Crucially, these effects were abrogated in YAP-deficient mice or upon pharmacological inhibition of the YAP-TEAD interaction, placing YAP-TEAD as a downstream effector of PPARα-driven hepatic growth and regeneration. This positions WY-14643 (Pirinixic Acid) as a unique pharmacological probe to dissect not only PPARα biology but also the crosstalk between metabolic and regenerative pathways.

Key Experimental Highlights

• Genetic Models: Liver-specific PPARα and YAP knockout mice clarified the requirement of both factors for WY-14643-induced hepatomegaly.
• Pharmacological Modulation: Inhibition of YAP-TEAD with verteporfin blocked WY-14643’s effects on liver size and regeneration.
• Regenerative Potential: Enhanced Ki67 and β-catenin staining demonstrated increased hepatocyte proliferation and cell cycle entry after WY-14643 administration.

This mechanistic dissection moves beyond the scope of prior reviews—such as this strategic guidance piece—by integrating the YAP-TEAD axis into the narrative of PPARα-driven hepatic biology.

Comparative Analysis: WY-14643 versus Conventional PPAR Modulators

Unique Features and Research Advantages

WY-14643 is distinguished from classic fibrates and other synthetic PPAR agonists by its higher selectivity for PPARα, tunable dual agonist potential, and broad solubility profile (soluble in DMSO and ethanol, but not water). Its documented capacity to down-regulate VCAM-1 and reduce monocyte adhesion in endothelial cells further sets it apart as an anti-inflammatory agent in endothelial cells, expanding its relevance to vascular inflammation models.

Functional Outcomes in Animal and Cellular Models

• Metabolic Improvements: Oral WY-14643 at 3 mg/kg/day for two weeks in high-fat diet rat models led to decreased plasma glucose, triglycerides, leptin, and visceral fat, while enhancing whole-body insulin sensitivity without increased body weight.
• Inflammatory Modulation: Pretreatment of cells with 250 μM WY-14643 significantly down-regulated TNF-α-induced VCAM-1 expression, supporting its anti-inflammatory utility.
• Regenerative Efficacy: Unlike many PPAR agonists, WY-14643’s role in promoting hepatocyte mitogenesis via Kupffer cell activation and modulation of hepatic TNFα mRNA is now mechanistically linked to regenerative signaling through YAP-TEAD.

For an in-depth comparison with translational and workflow-focused discussions, readers may consult this actionable deep-dive, which contrasts WY-14643 with conventional PPARα modulators in preclinical workflows. Our analysis here uniquely extends the conversation to regeneration and tissue remodeling, adding a new dimension to WY-14643’s application profile.

Advanced Applications: From Metabolic Disorders to Tissue Regeneration and Beyond

Metabolic Disorder Research and Insulin Sensitivity Enhancement

WY-14643’s robust capacity to regulate lipid metabolism and improve insulin sensitivity has made it an essential compound in the modeling of metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). By boosting fatty acid oxidation and reducing ectopic triglyceride accumulation, WY-14643 supports the study of metabolic homeostasis and therapeutic intervention strategies.

Exploring Anti-Inflammatory Mechanisms in Endothelial Cells

At the vascular interface, WY-14643’s ability to suppress TNF-α-mediated VCAM-1 expression and monocyte adhesion positions it as a powerful anti-inflammatory agent in endothelial cells. These findings enable researchers to dissect the intersection of metabolic and vascular inflammation, with implications for atherosclerosis and cardiovascular disease models.

Regenerative Medicine: WY-14643 as a Tool for Liver Growth and Repair

Perhaps the most novel application domain for WY-14643 is in regenerative medicine. By elucidating the molecular mechanisms by which PPARα activation—mediated by WY-14643—drives hepatocyte proliferation via the YAP-TEAD pathway, investigators can now explore targeted interventions for liver injury, partial hepatectomy recovery, and chronic hepatic disease. This application focus is distinct from prior content, which has largely concentrated on metabolic and inflammatory endpoints (see a comprehensive prior exploration). Our article synthesizes these findings with new mechanistic clarity, providing a unique roadmap for regenerative research pipelines.

Practical Considerations for Experimental Design and Compound Handling

• Solubility: WY-14643 is insoluble in water but dissolves readily in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance). Careful solvent selection is critical for in vitro and in vivo applications.
• Storage: Store the solid at -20°C. Solutions should be prepared fresh or used within short periods to maintain activity.
• Research Use Only: As supplied by APExBIO, WY-14643 is strictly for scientific research and not for diagnostic or therapeutic applications.

Conclusion and Future Outlook: WY-14643 as a Platform for Next-Generation Discovery

WY-14643 (Pirinixic Acid), available through APExBIO, is more than just a selective PPARα agonist for metabolic research. Its mechanistic reach now extends into the realms of regenerative biology, exemplified by its YAP-TEAD-mediated effects on liver growth and repair. As research continues to bridge metabolic, inflammatory, and regenerative processes, WY-14643 is poised to remain a platform molecule for next-generation investigation.

Future studies will benefit from integrating WY-14643 into multiplexed signaling investigations, systems biology models, and translational pipelines targeting both metabolic disorders and tissue regeneration. By leveraging its unique mechanistic profile, researchers can unlock new therapeutic paradigms at the intersection of metabolism and tissue repair.

For more information or to integrate this compound into your workflow, visit the WY-14643 (Pirinixic Acid) product page.